U.S. Biotech Stock News

Wendy's (WEN) is back in focus after quarterly results showed US$543 million in revenue that exceeded analyst expectations, but annual EBITDA guidance and same-store sales estimates fell short. See our latest analysis for Wendy's. The mixed earnings reaction fits into a weaker backdrop, with a 30 day share price return of 5.10% and a year to date share price return showing a decline of 15.79%, while the 1 year total shareholder return shows a decline of 45.03% and the 3 year total shareholder...

During March, International Bancshares Corporation’s short interest rose by 24%, climbing from 1,484,699 shares to 1,841,066 shares, marking a clear shift in positioning among traders. This rapid build-up in short positions, occurring even as analyst sentiment remains generally positive, highlights a growing divide between market participants’ expectations. We will examine how this sharp rise in short interest shapes International Bancshares’ investment narrative and what it may signal for...

Event Context and Recent Performance Snapshot Mettler-Toledo International (MTD) recently drew investor attention without a single clear headline event, as its shares closed at US$1,259.94, with a year to date total return of around an 11% decline and a 23.2% gain over the past year. See our latest analysis for Mettler-Toledo International. The recent 7 day share price return of 2.26% contrasts with a 90 day share price decline of 10.73%. However, the 1 year total shareholder return of 23.20%...

Trip.com Group has in the past few months faced an anti-monopoly probe in China over an AI hotel pricing tool, prompting multiple U.S. securities class action filings alleging misleading disclosures about regulatory risks. In response to regulatory scrutiny and partner complaints, Trip.com has shut down the AI pricing system, potentially reshaping how it balances market power with hotel partner relationships and its broader platform economics. We’ll now examine how Trip.com’s regulatory...

Why Cousins Properties is on investors’ radar Cousins Properties (CUZ) has attracted attention after a recent share price pullback, with the stock showing negative returns over the past month and past 3 months despite its established Sun Belt office portfolio. See our latest analysis for Cousins Properties. Over the past year, Cousins Properties has seen a 10.69% decline in total shareholder return, while the recent 7 day share price return of 5.25% hints at short term momentum building from...

Harmonic (HLIT) is back in focus after TDF, a major French broadcast infrastructure operator, upgraded its nationwide terrestrial network using Harmonic’s XOS and ProStream X platforms, spotlighting the company’s media processing capabilities. See our latest analysis for Harmonic. Despite the TDF and KBRO wins and new sports streaming features, Harmonic’s recent momentum has been mixed, with a 30 day share price return of a 7.35% decline contrasting with a 1 year total shareholder return of...

Artivion’s recent Q4 results showed revenue rising 19.2% year on year, driven by strong growth in stent grafts, On-X products, and preservation services, but coming in just 0.8% below analyst expectations. Despite delivering solid full-year 2025 adjusted revenue and EBITDA growth, Artivion’s relatively weaker performance versus peer estimates raises questions about how much near-term momentum investors should expect. Next, we’ll examine how this slight quarterly revenue miss, despite strong...

In early April 2026, Roivant Sciences reported mixed clinical updates, including Priovant’s launch of a Phase 2b/3 brepocitinib trial in lichen planopilaris and Immunovant’s Phase 3 batoclimab thyroid eye disease studies not meeting their primary endpoint. The brepocitinib program now spans four late-stage indications and has Priority Review for dermatomyositis, underscoring Roivant’s emphasis on high-need autoimmune conditions despite setbacks for batoclimab. We’ll now examine how the...

In late March 2026, Teva Pharmaceutical Industries reported three biosimilar milestones, including US FDA approval of PONLIMSI (denosumab-adet) as a biosimilar to Prolia for all its osteoporosis-related indications, alongside FDA and EMA acceptance of filings for a proposed Xolair (omalizumab) biosimilar across its full label. These advances highlight Teva’s effort to broaden its higher-value biopharmaceutical portfolio, using biosimilars to complement its generics base and support its Pivot...

Recent comments from television host Jim Cramer, who questioned Western Union (WU) as a growth idea despite its dividend appeal, have put the stock back in focus after a roughly 6.5% move higher. See our latest analysis for Western Union. The recent 6.5% share price move and 1 day share price return of 2.96% come against a weaker backdrop, with a 30 day share price return of 10.21% and a 1 year total shareholder return of 4.4% and 5 year total shareholder return of 49.31%. This suggests...

Mirum Pharmaceuticals (MIRM) has drawn fresh attention after reporting record quarterly net product revenue, raising full year revenue guidance, achieving its first GAAP profitability, and completing enrollment in several key clinical trials. See our latest analysis for Mirum Pharmaceuticals. The recent clinical and regulatory milestones appear to have fed into strong momentum, with a 90 day share price return of 20.62% and a 1 year total shareholder return of 124.05%. The current share price...

In March 2026, FTI Consulting, Inc. appointed Kelly Henney as Senior Managing Director and Australia Leader of its Information Governance, Privacy & Security practice within the Technology segment, based in Sydney. Her background in artificial intelligence governance, data privacy, and digital risk, combined with legal and banking experience, enhances FTI’s ability to advise clients on complex regulatory and compliance challenges. Next, we’ll examine how Henney’s artificial intelligence...

In March 2026, Flex LNG Ltd. announced a new time charter for the Flex Aurora with a Supermajor, securing a firm two-year term plus optional extensions that could keep the vessel employed through 2034 and lift the company’s total contract backlog to a minimum of 55 years, or up to 82 years if all options are used. This incremental charter backlog adds further revenue visibility at a time when the company has flagged potential revisions to its full-year 2026 guidance amid volatile LNG...

On March 18, 2026, Core Scientific, Inc. entered into an amendment to its Delayed-Draw Bridge Credit Agreement, increasing total term loan commitments by US$500.0 million to US$1.0 billion and drawing the full incremental amount on the closing date. This substantial expansion of borrowing capacity materially alters Core Scientific’s financial flexibility, potentially affecting how it funds high‑performance computing projects and manages its evolving capital structure. We’ll now examine how...

Why Phreesia’s latest guidance cut matters for investors Phreesia (PHR) has drawn fresh attention after issuing lower fiscal 2027 revenue guidance, tying the reset to weaker spending from pharmaceutical clients. The announcement triggered a sharp share price drop and several analyst downgrades. See our latest analysis for Phreesia. The lowered fiscal 2027 revenue outlook, combined with mixed fourth quarter results and analyst downgrades, has sharply shifted sentiment. A 7 day share price...

In late March 2026, investors reacted to easing geopolitical tensions and a broader relief rally as confidence improved around NextNav’s prospects for an FCC Notice of Proposed Rulemaking tied to its 5G-based terrestrial GPS backup system. This shift in sentiment highlights how progress toward a clearer regulatory path can become a central driver of interest in NextNav’s spectrum-backed positioning and timing platform. Now we’ll examine how growing optimism around the FCC regulatory...

Oil driven pullback puts BKV in focus The recent easing of U.S. Iran tensions pushed oil prices lower, dragging energy names with them as traders locked in gains after a strong run and technical gauges flagged oversold conditions across the sector. BKV (BKV) was caught in that macro driven move, with selling pressure tied less to company specific headlines and more to shifting sentiment toward oil and gas exposure in the short term. See our latest analysis for BKV. That macro volatility sits...

On March 30, 2026, Option Care Health expanded its revolving credit facility by US$450 million to US$850 million and increased its share repurchase authorization to US$1 billion, while reaffirming its 2026 guidance. The move strengthens liquidity and signals management’s confidence in cash generation, giving the company more flexibility to fund growth and return capital to shareholders. We’ll now examine how the expanded US$1 billion buyback authorization reshapes Option Care Health’s...

Intuitive Machines (LUNR) is back in focus after securing a US$180.4 million NASA contract for its IM-5 lunar South Pole mission, the company’s fifth Commercial Lunar Payload Services award and a meaningful pipeline milestone. See our latest analysis for Intuitive Machines. The latest NASA award appears to have reignited interest in Intuitive Machines, with a 1-day share price return of 18.53% and a 7-day share price return of 36.93%. The 1-year total shareholder return of 249.20% points to...

Commvault Systems (CVLT) is back in focus after announcing a new alliance with NetApp to offer an integrated data protection and cyber resilience solution that leans heavily on AI driven ransomware detection and automated recovery. See our latest analysis for Commvault Systems. The recent AI centric alliances with NetApp and Microsoft Security come after a sharp 90 day share price return of negative 35.63% and a 1 year total shareholder return of negative 42.64%, even though the 3 year total...

For investors wondering whether Constellation Brands is starting to look like a value opportunity or is still pricing in a premium future, this article walks through key checks that can help you frame that question for yourself. The stock last closed at US$151.20, with a 7.1% return year to date. However, the 1 year return is a 10.8% loss, and the 3 and 5 year returns are 28.6% and 26.5% losses respectively. Recent coverage around Constellation Brands has focused on how investors are...

Vertiv Holdings Co recently committed about US$50,000,000 to expand its Ironton manufacturing site and Westerville headquarters in Ohio, aiming to lift liquid cooling and chilled water system capacity by roughly 45% and add hundreds of jobs through 2029. By broadening its U.S. and broader Americas footprint for AI-ready power and thermal infrastructure, Vertiv is tightening supply chains and positioning itself as an end-to-end provider for rapidly scaling data center and high‑density...

American Assets Trust, Inc. recently amended and restated its credit agreement, lifting its revolving credit line from US$400,000,000 to US$500,000,000 and extending both the revolver and a US$100,000,000 term loan to April 1, 2030, with additional extension options. This larger, longer-dated credit facility increases the REIT’s financial flexibility, potentially affecting how it funds acquisitions, development, and ongoing operations. Next, we’ll consider how the larger US$500,000,000...

Qnity Electronics stock: what recent performance says about investor interest Qnity Electronics (Q) is drawing attention after a strong past 3 months, with the stock up about 37%. The latest close sits at US$116.53 and recent daily moves remain mixed. See our latest analysis for Qnity Electronics. The recent 37.1% three-month share price return suggests solid momentum building for Qnity Electronics, despite a one-day share price decline of 1.7% and only modest movement over the past month. If...